GLP1-based obesity medicines, such as Ozempic and Wegovy, have surged in popularity and become the subject of intense public ...

A/S, a global healthcare company specializing in diabetes care and other chronic conditions, has been at the forefront of the rapidly expanding GLP-1 market. With a market capitalization of $376.79 ...